Table 1.
Clinical characteristics of the cohort
| Clinical Characteristics | n = 523 |
|---|---|
| Median age (range), years | 59 (18–92) |
| Median follow-up for patients without a metastatic event, years (range) | 7.5 (5.0–16.5) |
| Recurrence/distant metastasis | 142/111 |
| Median time to first recurrence, years (range) | 1.2 (0.0–10.0) |
| AJCC stage | |
| I (total) | 264 (50%) |
| IA | 108 |
| IB | 76 |
| Unknown substagea | 80 |
| II (total) | 93 (18%) |
| IIA | 35 |
| IIB | 26 |
| IIC | 17 |
| Unknown substage | 15 |
| III (total) | 166 (32%) |
| IIIA | 69 |
| IIIB | 57 |
| IIIC | 35 |
| Unknown substage | 5 |
| Breslow thickness | |
| Median (range), mm | 1.2 (0.1–29.0) |
| ≤ 1 mm | 223 (43%) |
| > 1 mm | 296 (56%) |
| Unreported | 4 (1%) |
| Mitotic index | |
| < 1/mm2 | 99 (19%) |
| ≥ 1/mm2 | 240 (46%) |
| Unreported | 184 (35%) |
| Ulceration | |
| Absent | 309 (59%) |
| Present | 133 (26%) |
| Unreported | 81 (15%) |
| SLN status | |
| Untested | 186 (36%) |
| Negative | 180 (34%) |
| Positive | 157 (30%) |
| GEP Class | |
| Class 1 | 314 (60%) |
| Class 2 | 209 (40%) |
SLN sentinel lymph node, GEP gene expression profile
aSubstage information was not available in clinical documentation for these patients